Trials / Completed
CompletedNCT01343121
Measurement of Gemcitabine Metabolites in Blood and Urine as Predictors of Response to GemX Bladder Radiotherapy
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- The Christie NHS Foundation Trust · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the hypothesis that plasma, peripheral blood mononuclear cell and urine levels of Gemcitabine and its metabolites, 30 mins or 2 hours post infusion, predict response to GemX chemoradiation at first check cystoscopy, 3 months from the end of radiotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | sample collection | Blood samples will be collected on days 1, 8, 15 and 22. They will be taken 30 minutes and 2 hours post Gemcitabine infusion. |
| OTHER | sample collection | Urine will be collected on days 1, 8, 15 and 22. They will be taken pre gemcitabine and 2 hours post Gemcitabine |
| OTHER | Sample Collection | Quality of Life (QOL) questionnaires given to the patient at each visit |
Timeline
- Start date
- 2012-02-02
- Primary completion
- 2017-11-24
- Completion
- 2017-11-24
- First posted
- 2011-04-27
- Last updated
- 2021-08-13
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01343121. Inclusion in this directory is not an endorsement.